Step by Step

INTRODUCTION

ABIM MOC Activity ID

11/11/2025 - MGR: The Evolution of Hemophilia - From Cryoprecipitate to Gene Therapy: A Success Story

QUIZ

EVALUATION

CERTIFICATE

INTRODUCTION

Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Explain bi-specific antibody therapy for hemophilia A
  • Describe anti-TFPI therapy for hemophilia
  • Evaluate the need for new therapies in hemophilia

Suggested Additional Reading & Joint Accreditation Statement - Note: This Accreditation Statement Supersedes All Other Statements:

Suggested Additional Reading:

  • Samelson-Jones BJ, Small JC, George LA. Roctavian gene therapy for hemophilia A. Blood Advances. 2024; 8:5179-5189.
  • Samelson-Jones BJ and George LA. Adeno-associated virus gene therapy for hemophilia. Annual Review of Medicine. 2023; 74:231-247.
  • Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. New England Journal of Medicine. 2022. 386:1013-1025.

Joint Accreditation Statement

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician (CME)

The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Each physician should only claim credit commensurate with the extent of their participation in the activity.


Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

Authors:
Craig Seaman, MD., MS. — Assistant Professor of Meidicne, Division of Classical Hematology, University of Pittsburgh School of Medicine
Dr. Seaman is a consultant with CSL Behring, Novo Nordisk, Pfizer, and Takeda.
Frederico Xavier, MD., MS. — Associate Professor of Pediatric Hematology/Oncology, University of Pittsburgh
UPMC Children’s Hospital of Pittsburgh, Pediatric Clinical Director
Hemophilia Center of Western Pennsylvania
Dr Xavier discloses he is a member of the Speakers' Bureau for Genentech and Sanofi. He is a consultant for new products in Hemophilia.
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity is approved for AMA PRA Category 1 Credit™

The University of Pittsburgh is an affirmative action, equal opportunity institution.